Septerna, Inc. is leading the way in GPCR drug discovery with innovative programs like SEP-479 and SEP-631.
The company is focused on advancing potential first-in-class oral small molecules for various diseases.
Their Native Complex Platform holds promising opportunities for mast cell-driven diseases.
SEP-479 PTH1R Agonist Program
Potential first-in-class oral small molecule for hypoparathyroidism; Phase 1 clinical trial initiation planned in 1H 2026.
SEP-631 MRGPRX2 NAM Program
Pipeline-in-a-product for mast cell-driven diseases like CSU; Phase 1 SAD/MAD results expected at AAAAI Annual Meeting in March 2026.
TSHR NAM Program
Potential disease-modifying treatment for Graves' disease and TED; progressing compounds towards development candidate selection.
- Septerna is set to initiate a Phase 1 clinical trial for SEP-479 in the first half of 2026, pending regulatory approvals.
- The company aims to present topline data for SEP-631 at the AAAAI Annual Meeting in March 2026, a crucial milestone for their programs.
- Collaborating with Novo Nordisk, Septerna is working on multiple potential oral small molecule therapies for obesity, type 2 diabetes, and cardiometabolic diseases.
With strong programs like SEP-479 and SEP-631, Septerna is poised to make significant strides in GPCR drug discovery and treatment development.